Multiple sclerosis: Immunopathology and treatment update

Brain Sciences

Volumn 7, Issue 7, 2017, Pages

  Dargahi, Narges ^a   Katsara, Maria ^b   Tselios, Theodore ^c   Androutsou, Maria Eleni ^d   De Courten, Maximilian ^a   Matsoukas, John ^e   Apostolopoulos, Vasso ^a  

^a VICTORIA UNIVERSITY   (Australia)

^b Medic   (Greece)

^c UNIVERSITY OF PATRAS   (Greece)

^d VIANEX SA   (Greece)

^e Eldrug SA   (Greece)

Author keywords

Drug delivery; Immunotherapy; Multiple sclerosis; Vaccine

Indexed keywords

ALEMTUZUMAB; ALTERED PEPTIDE LIGAND; BETA1A INTERFERON; CORTICOSTEROID; CYCLOPEPTIDE; CYCLOPHOSPHAMIDE; DACLIZUMAB; DISEASE MODIFYING ANTIRHEUMATIC DRUG; DNA VACCINE; FAMPRIDINE; FINGOLIMOD; FUMARIC ACID DIMETHYL ESTER; GLATIRAMER; INTERFERON BETA SERINE; MITOXANTRONE; NANOPARTICLE; NATALIZUMAB; OCRELIZUMAB; OFATUMUMAB; PEGINTERFERON BETA1A; PEPTIDES AND PROTEINS; TERIFLUNOMIDE; UNCLASSIFIED DRUG;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CD4+ T LYMPHOCYTE; CELL PROLIFERATION; COMPLEMENT DEPENDENT CYTOTOXICITY; DENDRITIC CELL; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; IMMUNOPATHOLOGY; IMMUNOTHERAPY; MESENCHYMAL STEM CELL TRANSPLANTATION; MULTICENTER STUDY (TOPIC); MULTIPLE SCLEROSIS; NONHUMAN; OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REGULATORY T LYMPHOCYTE; REVIEW;

EID: 85023768691     PISSN: None     EISSN: 20763425     Source Type: Journal    
DOI: 10.3390/brainsci7070078     Document Type: Review

References (189)

1. Compston, A., Coles, A. Multiple sclerosis. Lancet 2002, 359, 1221-1231.
2. Grytten, N., Torkildsen, O., Myhr, K. M. Time trends in the incidence and prevalence of multiple sclerosis in norway during eight decades. Acta Neurol. Scand. 2015, 132, 29-36.
3. Antel, J., Antel, S., Caramanos, Z., Arnold, D.L., Kuhlmann, T. Primary progressive multiple sclerosis: Part of the ms disease spectrum or separate disease entity? Acta Neuropathol. 2012, 123, 627-638.
4. Sadovnick, A.D., Ebers, G.C., Dyment, D.A., Risch, N.J. Evidence for genetic basis of multiple sclerosis. Lancet 1996, 347, 1728-1730.
5. Dai, H., Ciric, B., Zhang, G.X., Rostami, A. Interleukin-10 plays a crucial role in suppression of experimental autoimmune encephalomyelitis by bowman-birk inhibitor. J. Neuroimmunol. 2012, 245, 1-7.
6. Hemmer, B., Nessler, S., Zhou, D., Kieseier, B., Hartung, H.P. Immunopathogenesis and immunotherapy of multiple sclerosis. Nat. Clin. Pract. Neurol. 2006, 2, 201-211.
7. Sospedra, M., Martin, R. Immunology of multiple sclerosis. Annu. Rev. Immunol. 2005, 23, 683-747.
8. Rieckmann, P. Improving ms patient care. J. Neurol. Suppl. 2004, 251, v69-v73.
9. Katsara, M., Matsoukas, J., Deraos, G., Apostolopoulos, V. Towards immunotherapeutic drugs and vaccines against multiple sclerosis. Acta Biochim. Biophys. Sin. 2008, 40, 636-642.
10. Lublin, F.D., Reingold, S.C. Defining the clinical course of multiple sclerosis: Results of an international survey. Neurology 1996, 46, 907-911.
11. Eckstein, C., Bhatti, M.T. Currently approved and emerging oral therapies in multiple sclerosis: An update for the ophthalmologist. Surv. Ophthalmol. 2016, 61, 318-332.
12. Polman, C.H., Reingold, S.C., Banwell, B., Clanet, M., Cohen, J.A., Filippi, M., Fujihara, K., Havrdova, E., Hutchinson, M., Kappos, L., et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the mcdonald criteria. Ann. Neurol. 2011, 69, 292-302.
13. Lunde Larsen, L.S., Larsson, H.B.W., Frederiksen, J.L. The value of conventional high-field mri in ms in the light of the mcdonald criteria: A literature review. Acta Neurol. Scand. 2010, 122, 149-158.
14. Gafson, A., Giovannoni, G., Hawkes, C.H. The diagnostic criteria for multiple sclerosis: From charcot to mcdonald. Mult. Scler. Relat. Disord. 2012, 1, 9-14.
15. Mahad, D.H., Trapp, B.D., Lassmann, H. Pathological mechanisms in progressive multiple sclerosis. Lancet Neurol. 2015, 14, 183-193.
16. Minagar, A., Alexander, J.S. Blood-brain barrier disruption in multiple sclerosis. Mult. Scler. 2003, 9, 540-549.
17. Steinman, L. Multiple sclerosis: A coordinated immunological attack against myelin in the central nervous system. Cell 1996, 85, 299-302.
18. Bennett, J., Basivireddy, J., Kollar, A., Biron, K.E., Reickmann, P., Jefferies, W.A., McQuaid, S. Blood-brain barrier disruption and enhanced vascular permeability in the multiple sclerosis model eae. J. Neuroimmunol. 2010, 229, 180-191.
19. Farjam, M., Zhang, G.X., Ciric, B., Rostami, A. Emerging immunopharmacological targets in multiple sclerosis. J. Neurol. Sci. 2015, 358, 22-30.
20. Dandekar, A.A., Wu, G.F., Pewe, L., Perlman, S. Axonal damage is t cell mediated and occurs concomitantly with demyelination in mice infected with a neurotropic coronavirus. J. Virol. 2001, 75, 6115-6120.
21. Jiang, J., Kelly, K.A. Phenotype and function of regulatory t cells in the genital tract. Curr. Trends Immunol. 2011, 12, 89-94.
22. Bianchini, E., De Biasi, S., Simone, A.M., Ferraro, D., Sola, P., Cossarizza, A., Pinti, M. Invariant natural killer T cells and mucosal-associated invariant T cells in multiple sclerosis. Immunol. Lett. 2017, 183, 1-7.
23. Tabarkiewicz, J., Pogoda, K., Karczmarczyk, A., Pozarowski, P., Giannopoulos, K. The role of il-17 and th17 lymphocytes in autoimmune diseases. Arch. Immunol. Ther. Exp. 2015, 63, 435-449.
24. Van Hamburg, J.P., Asmawidjaja, P.S., Davelaar, N., Mus, A.M.C., Colin, E.M., Hazes, J.M.W., Dolhain, R.J.E.M., Lubberts, E. Th17 cells, but not th1 cells, from patients with early rheumatoid arthritis are potent inducers of matrix metalloproteinases and proinflammatory cytokines upon synovial fibroblast interaction, including autocrine interleukin-17a production. Arthritis Rheum. 2011, 63, 73-83.
25. Dolati, S., Babaloo, Z., Jadidi-Niaragh, F., Ayromlou, H., Sadreddini, S., Yousefi, M. Multiple sclerosis: Therapeutic applications of advancing drug delivery systems. Biomed. Pharmacother. 2017, 86, 343-353.
26. Münzel, E.J., Williams, A. Promoting remyelination in multiple sclerosis-recent advances. Drugs 2013, 73, 2017-2029.
27. Inglese, M., Petracca, M. Therapeutic strategies in multiple sclerosis: A focus on neuroprotection and repair and relevance to schizophrenia. Schizophr. Res. 2015, 161, 94-101.
28. Koriem, K.M.M. Multiple sclerosis: New insights and trends. Asian Pac. J. Trop. Biomed. 2016, 6, 429-440.
29. Kallaur, A.P., Lopes, J., Oliveira, S.R., Simão, A.N., Reiche, E.M., de Almeida, E.R.D., Morimoto, H.K., de Pereira, W.L., Alfieri, D.F., Borelli, S.D., et al. Immune-inflammatory and oxidative and nitrosative stress biomarkers of depression symptoms in subjects with multiple sclerosis: Increased peripheral inflammation but less acute neuroinflammation. Mol. Neurobiol. 2016, 53, 5191-5202.
30. Mirshafiey, A., Jadidi-Niaragh, F. Prostaglandins in pathogenesis and treatment of multiple sclerosis. Immunopharmacol. Immunotoxicol. 2010, 32, 543-554.
31. Fischer, M.T., Sharma, R., Lim, J.L., Haider, L., Frischer, J.M., Drexhage, J., Mahad, D., Bradl, M., Van Horssen, J., Lassmann, H. Nadph oxidase expression in active multiple sclerosis lesions in relation to oxidative tissue damage and mitochondrial injury. Brain 2012, 135, 886-899.
32. Van Kaer, L., Wu, L., Parekh, V.V. Natural killer t cells in multiple sclerosis and its animal model, experimental autoimmune encephalomyelitis. Immunology 2015, 146, 1-10.
33. Gigli, G., Caielli, S., Cutuli, D., Falcone, M. Innate immunity modulates autoimmunity: Type 1 interferon-beta treatment in multiple sclerosis promotes growth and function of regulatory invariant natural killer t cells through dendritic cell maturation. Immunology 2007, 122, 409-417.
34. Araki, M., Kondo, T., Gumperz, J.E., Brenner, M.B., Miyake, S., Yamamura, T. Th2 bias of cd4+ nkt cells derived from multiple sclerosis in remission. Int. Immunol. 2003, 15, 279-288.
35. Mars, L.T., Laloux, V., Goude, K., Desbois, S., Saoudi, A., Van Kaer, L., Lassmann, H., Herbelin, A., Lehuen, A., Liblau, R.S. Cutting edge: V alpha 14-j alpha 281 nkt cells naturally regulate experimental autoimmune encephalomyelitis in nonobese diabetic mice. J. Immunol. 2002, 168, 6007-6011.
36. Van Kaer, L. Alpha-galactosylceramide therapy for autoimmune diseases: Prospects and obstacles. Nat. Rev. Immunol. 2005, 5, 31-42.
37. Van Kaer, L., Parekh, V.V., Wu, L. Invariant nk t cells: Potential for immunotherapeutic targeting with glycolipid antigens. Immunotherapy 2011, 3, 59-75.
38. Jahng, A., Maricic, I., Aguilera, C., Cardell, S., Halder, R.C., Kumar, V. Prevention of autoimmunity by targeting a distinct, noninvariant cd1d-reactive t cell population reactive to sulfatide. J. Exp. Med. 2004, 199, 947-957.
39. Napier, R.J., Adams, E.J., Gold, M.C., Lewinsohn, D.M. The role of mucosal associated invariant t cells in antimicrobial immunity. Front. Immunol. 2015, 6, 344.
40. Kjer-Nielsen, L., Patel, O., Corbett, A.J., Le Nours, J., Meehan, B., Liu, L., Bhati, M., Chen, Z., Kostenko, L., Reantragoon, R., et al. Mr1 presents microbial vitamin b metabolites to mait cells. Nature 2012, 491, 717-723.
41. Abrahamsson, S.V., Angelini, D.F., Dubinsky, A.N., Morel, E., Oh, U., Jones, J.L., Carassiti, D., Reynolds, R., Salvetti, M., Calabresi, P.A., et al. Non-myeloablative autologous haematopoietic stem cell transplantation expands regulatory cells and depletes il-17 producing mucosal-associated invariant t cells in multiple sclerosis. Brain 2013, 136, 2888-2903.
42. Miyazaki, Y., Miyake, S., Chiba, A., Lantz, O., Yamamura, T. Mucosal-associated invariant t cells regulate th1 response in multiple sclerosis. Int. Immunol. 2011, 23, 529-535.
43. Kohm, A.P., Carpentier, P.A., Anger, H.A., Miller, S.D. Cutting edge: CD4+CD25+ regulatory t cells suppress antigen-specific autoreactive immune responses and central nervous system inflammation during active experimental autoimmune encephalomyelitis. J. Immunol. 2002, 169, 4712-4716.
44. Zhang, X., Koldzic, D.N., Izikson, L., Reddy, J., Nazareno, R.F., Sakaguchi, S., Kuchroo, V.K., Weiner, H.L. Il-10 is involved in the suppression of experimental autoimmune encephalomyelitis by CD25+CD4+ regulatory t cells. Int. Immunol. 2004, 16, 249-256.
45. McGeachy, M.J., Stephens, L.A., Anderton, S.M. Natural recovery and protection from autoimmune encephalomyelitis: Contribution of CD4+CD25+ regulatory cells within the central nervous system. J. Immunol. 2005, 175, 3025-3032.
46. Matejuk, A., Bakke, A.C., Hopke, C., Dwyer, J., Vandenbark, A.A., Offner, H. Estrogen treatment induces a novel population of regulatory cells, which suppresses experimental autoimmune encephalomyelitis. J. Neurosci. Res. 2004, 77, 119-126.
47. Weber, M.S., Prod’homme, T., Youssef, S., Dunn, S.E., Rundle, C.D., Lee, L., Patarroyo, J.C., Stuve, O., Sobel, R.A., Steinman, L., et al. Type ii monocytes modulate t cell-mediated central nervous system autoimmune disease. Nat. Med. 2007, 13, 935-943.
48. Beyersdorf, N., Gaupp, S., Balbach, K., Schmidt, J., Toyka, K.V., Lin, C.H., Hanke, T., Hunig, T., Kerkau, T., Gold, R. Selective targeting of regulatory t cells with cd28 superagonists allows effective therapy of experimental autoimmune encephalomyelitis. J. Exp. Med. 2005, 202, 445-455.
49. Zozulya, A.L., Wiendl, H. The role of regulatory t cells in multiple sclerosis. Nat. Clin. Pract. Neurol. 2008, 4, 384-398.
50. Diebold, M., Derfuss, T. Immunological treatment of multiple sclerosis. Semin. Hematol. 2016, 53 (Suppl 1), S54-S57.
51. Mosser, D.M., Edwards, J.P. Exploring the full spectrum of macrophage activation. Nat. Rev. Immunol. 2008, 8, 958-969.
52. Bruck, W., Sommermeier, N., Bergmann, M., Zettl, U., Goebel, H.H., Kretzschmar, H.A., Lassmann, H. Macrophages in multiple sclerosis. Immunobiology 1996, 195, 588-600.
53. Vogel, D.Y., Vereyken, E.J., Glim, J.E., Heijnen, P.D., Moeton, M., van der Valk, P., Amor, S., Teunissen, C.E., van Horssen, J., Dijkstra, C.D. Macrophages in inflammatory multiple sclerosis lesions have an intermediate activation status. J. Neuroinflamm. 2013, 10, 35.
54. Peferoen, L.A., Vogel, D.Y., Ummenthum, K., Breur, M., Heijnen, P.D., Gerritsen, W.H., Peferoen-Baert, R.M., van der Valk, P., Dijkstra, C.D., Amor, S. Activation status of human microglia is dependent on lesion formation stage and remyelination in multiple sclerosis. J. Neuropathol. Exp. Neurol. 2015, 74, 48-63.
55. Miron, V.E., Boyd, A., Zhao, J.W., Yuen, T.J., Ruckh, J.M., Shadrach, J.L., van Wijngaarden, P., Wagers, A.J., Williams, A., Franklin, R.J., et al. M2 microglia and macrophages drive oligodendrocyte differentiation during cns remyelination. Nat. Neurosci. 2013, 16, 1211-1218.
56. Liu, C., Li, Y., Yu, J., Feng, L., Hou, S., Liu, Y., Guo, M., Xie, Y., Meng, J., Zhang, H., et al. Targeting the shift from m1 to m2 macrophages in experimental autoimmune encephalomyelitis mice treated with fasudil. PLoS ONE 2013, 8, e54841.
57. Apostolopoulos, V., de Courten, M.P., Stojanovska, L., Blatch, G.L., Tangalakis, K., de Courten, B. The complex immunological and inflammatory network of adipose tissue in obesity. Mol. Nutr. Food Res. 2016, 60, 43-57.
58. Wu, Q., Wang, Q., Mao, G., Dowling, C.A., Lundy, S.K., Mao-Draayer, Y. Dimethyl fumarate selectively reduces memory t cells and shifts the balance between th1/th17 and th2 in multiple sclerosis patients. J. Immunol. 2017, 198, 3069-3080.
59. Apostolopoulos, V., Deraos, G., Matsoukas, M.T., Day, S., Stojanovska, L., Tselios, T., Androutsou, M.E., Matsoukas, J. Cyclic citrullinated mbp87-99 peptide stimulates t cell responses: Implications in triggering disease. Bioorg. Med. Chem. 2017, 25, 528-538.
60. Deraos, G., Chatzantoni, K., Matsoukas, M.T., Tselios, T., Deraos, S., Katsara, M., Papathanasopoulos, P., Vynios, D., Apostolopoulos, V., Mouzaki, A., et al. Citrullination of linear and cyclic altered peptide ligands from myelin basic protein (mbp(87-99)) epitope elicits a th1 polarized response by t cells isolated from multiple sclerosis patients: Implications in triggering disease. J. Med. Chem. 2008, 51, 7834-7842.
61. Deraos, G., Rodi, M., Kalbacher, H., Chatzantoni, K., Karagiannis, F., Synodinos, L., Plotas, P., Papalois, A., Dimisianos, N., Papathanasopoulos, P., et al. Properties of myelin altered peptide ligand cyclo(87-99) (ala91,ala96)mbp87-99 render it a promising drug lead for immunotherapy of multiple sclerosis. Eur. J. Med. Chem. 2015, 101, 13-23.
62. Katsara, M., Deraos, G., Tselios, T., Matsoukas, J., Apostolopoulos, V. Design of novel cyclic altered peptide ligands of myelin basic protein mbp83-99 that modulate immune responses in sjl/j mice. J. Med. Chem. 2008, 51, 3971-3978.
63. Katsara, M., Deraos, G., Tselios, T., Matsoukas, M.T., Friligou, I., Matsoukas, J., Apostolopoulos, V. Design and synthesis of a cyclic double mutant peptide (cyclo(87-99)[a91,a96]mbp87-99) induces altered responses in mice after conjugation to mannan: Implications in the immunotherapy of multiple sclerosis. J. Med. Chem. 2009, 52, 214-218.
64. Katsara, M., Deraos, S., Tselios, T.V., Pietersz, G., Matsoukas, J., Apostolopoulos, V. Immune responses of linear and cyclic plp139-151 mutant peptides in sjl/j mice: Peptides in their free state versus mannan conjugation. Immunotherapy 2014, 6, 709-724.
65. Katsara, M., Minigo, G., Plebanski, M., Apostolopoulos, V. The good, the bad and the ugly: How altered peptide ligands modulate immunity. Expert Opin. Biol. Ther. 2008, 8, 1873-1884.
66. Katsara, M., Tselios, T., Deraos, S., Deraos, G., Matsoukas, M.T., Lazoura, E., Matsoukas, J., Apostolopoulos, V. Round and round we go: Cyclic peptides in disease. Curr. Med. Chem. 2006, 13, 2221-2232.
67. Katsara, M., Yuriev, E., Ramsland, P.A., Deraos, G., Tselios, T., Matsoukas, J., Apostolopoulos, V. A double mutation of mbp83-99 peptide induces il-4 responses and antagonizes ifn-γ responses. J. Neuroimmunol. 2008, 200, 77-89.
68. Katsara, M., Yuriev, E., Ramsland, P.A., Deraos, G., Tselios, T., Matsoukas, J., Apostolopoulos, V. Mannosylation of mutated mbp83-99 peptides diverts immune responses from th1 to th2. Mol. Immunol. 2008, 45, 3661-3670.
69. Katsara, M., Yuriev, E., Ramsland, P.A., Tselios, T., Deraos, G., Lourbopoulos, A., Grigoriadis, N., Matsoukas, J., Apostolopoulos, V. Altered peptide ligands of myelin basic protein (mbp87-99) conjugated to reduced mannan modulate immune responses in mice. Immunology 2009, 128, 521-533.
70. Matsoukas, J., Apostolopoulos, V., Kalbacher, H., Papini, A.M., Tselios, T., Chatzantoni, K., Biagioli, T., Lolli, F., Deraos, S., Papathanassopoulos, P., et al. Design and synthesis of a novel potent myelin basic protein epitope 87-99 cyclic analogue: Enhanced stability and biological properties of mimics render them a potentially new class of immunomodulators. J. Med. Chem. 2005, 48, 1470-1480.
71. Tselios, T., Apostolopoulos, V., Daliani, I., Deraos, S., Grdadolnik, S., Mavromoustakos, T., Melachrinou, M., Thymianou, S., Probert, L., Mouzaki, A., et al. Antagonistic effects of human cyclic mbp(87-99) altered peptide ligands in experimental allergic encephalomyelitis and human t-cell proliferation. J. Med. Chem. 2002, 45, 275-283.
72. Tselios, T.V., Lamari, F.N., Karathanasopoulou, I., Katsara, M., Apostolopoulos, V., Pietersz, G.A., Matsoukas, J.M., Karamanos, N.K. Synthesis and study of the electrophoretic behavior of mannan conjugates with cyclic peptide analogue of myelin basic protein using lysine-glycine linker. Anal. Biochem. 2005, 347, 121-128.
73. Tseveleki, V., Tselios, T., Kanistras, I., Koutsoni, O., Karamita, M., Vamvakas, S.S., Apostolopoulos, V., Dotsika, E., Matsoukas, J., Lassmann, H., et al. Mannan-conjugated myelin peptides prime non-pathogenic th1 and th17 cells and ameliorate experimental autoimmune encephalomyelitis. Exp. Neurol. 2015, 267, 254-267.
74. Deng, Y., Wang, Z., Chang, C., Lu, L., Lau, C.S., Lu, Q. Th9 cells and il-9 in autoimmune disorders: Pathogenesis and therapeutic potentials. Hum. Immunol. 2017, 78, 120-128.
75. Volpe, E., Batistini, L., Borsellino, G. Advances in t helper 17 cell biology: Pathogenic role and potential therapy in multiple sclerosis. Mediat. Inflamm. 2015, 475158.
76. Rolla, S., Bardina, V., De Mercanti, S., Quaglino, P., De Palma, R., Gned, D., Brusa, D., Durelli, L., Novelli, F., Clerico, M. Th22 cells are expanded in multiple sclerosis and are resistant to ifn-beta. J. Leukoc. Biol. 2014, 96, 1155-1164.
77. Muls, N., Nasr, Z., Dang, H.A., Sindic, C., van Pesch, V. Il-22, gm-csf and il-17 in peripheral CD4+ t cell subpopulations during multiple sclerosis relapses and remission. Impact of corticosteroid therapy. PLoS ONE 2017, 12, e0173780.
78. Iwasaki, Y., Fujio, K., Okamura, T., Yamamoto, K. Interleukin-27 in t cell immunity. Int. J. Mol. Sci. 2015, 16, 2851-2863.
79. Naderi, S., Hejazi, Z., Shajarian, M., Alsahebfosoul, F., Etemadifar, M., Sedaghat, N. Il-27 plasma level in relapsing remitting multiple sclerosis subjects: The double-faced cytokine. J. Immunoass. Immunochem. 2016, 37, 659-670.
80. Senecal, V., Deblois, G., Beauseigle, D., Schneider, R., Brandenburg, J., Newcombe, J., Moore, C.S., Prat, A., Antel, J., Arbour, N. Production of il-27 in multiple sclerosis lesions by astrocytes and myeloid cells: Modulation of local immune responses. Glia 2016, 64, 553-569.
81. Kawanokuchi, J., Takeuchi, H., Sonobe, Y., Mizuno, T., Suzumura, A. Interleukin-27 promotes inflammatory and neuroprotective responses in microglia. Clin. Exp. Neuroimmunol. 2013, 4, 36-45.
82. Sawcer, S., Hellenthal, G. The major histocompatibility complex and multiple sclerosis: A smoking gun? Brain 2011, 134, 638-640.
83. Dressel, A., Chin, J.L., Sette, A., Gausling, R., Hollsberg, P., Hafler, D.A. Autoantigen recognition by human cd8 t cell clones: Enhanced agonist response induced by altered peptide ligands. J. Immunol. 1997, 159, 4943-4951.
84. Tzartos, J.S., Friese, M.A., Craner, M.J., Palace, J., Newcombe, J., Esiri, M.M., Fugger, L. Interleukin-17 production in central nervous system-infiltrating t cells and glial cells is associated with active disease in multiple sclerosis. Am. J. Pathol. 2008, 172, 146-155.
85. Salehi, Z., Doosti, R., Beheshti, M., Janzamin, E., Sahraian, M.A., Izad, M. Differential frequency of CD8+ T cell subsets in multiple sclerosis patients with various clinical patterns. PLoS ONE 2016, 11, e0159565.
86. Disanto, G., Morahan, J.M., Barnett, M.H., Giovannoni, G., Ramagopalan, S.V. The evidence for a role of b cells in multiple sclerosis. Neurology 2012, 78, 823-832.
87. Wekerle, H. B cells in multiple sclerosis. Autoimmunity 2017, 50, 57-60.
88. Winger, R.C., Zamvil, S.S. Antibodies in multiple sclerosis oligoclonal bands target debris. Proc. Natl. Acad. Sci. USA 2016, 113, 7696-7698.
89. Huang, Y.M., Xiao, B.G., Ozenci, V., Kouwenhoven, M., Teleshova, N., Fredrikson, S., Link, H. Multiple sclerosis is associated with high levels of circulating dendritic cells secreting pro-inflammatory cytokines. J. Neuroimmunol. 1999, 99, 82-90.
90. Kong, Y.Y., Fuchsberger, M., Xiang, S.D., Apostolopoulos, V., Plebanski, M. Myeloid derived suppressor cells and their role in diseases. Curr. Med. Chem. 2013, 20, 1437-1444.
91. Wegner, A., Verhagen, J., Wraith, D.C. Myeloid-derived suppressor cells mediate tolerance induction in autoimmune disease. Immunology 2017, 151, 26-42.
92. Yu, J., Du, W., Yan, F., Wang, Y., Li, H., Cao, S., Yu, W., Shen, C., Liu, J., Ren, X. Myeloid-derived suppressor cells suppress antitumor immune responses through ido expression and correlate with lymph node metastasis in patients with breast cancer. J. Immunol. 2013, 190, 3783-3797.
93. Filippini, G., Brusaferri, F., Sibley, W.A., Citterio, A., Ciucci, G., Midgard, R., Candelise, L. Corticosteroids or acth for acute exacerbations in multiple sclerosis. Cochrane Database Syst. Rev. 2000.
94. Havrdova, E., Zivadinov, R., Krasensky, J., Dwyer, M.G., Novakova, I., Dolezal, O., Ticha, V., Dusek, L., Houzvickova, E., Cox, J.L., et al. Randomized study of interferon beta-1a, low-dose azathioprine, and low-dose corticosteroids in multiple sclerosis. Mult. Scler. 2009, 15, 965-976.
95. Morrow, S.A., Metz, L.M., Kremenchutzky, M. High dose oral steroids commonly used to treat relapses in canadian ms clinics. Can. J. Neurol. Sci. 2009, 36, 213-215.
96. Myhr, K.M., Mellgren, S.I. Corticosteroids in the treatment of multiple sclerosis. Acta Neurol. Scand. 2009, 120, 73-80.
97. Van Der Voort, L.F., Visser, A., Knol, D.L., Oudejans, C.B.M., Polman, C.H., Killestein, J. Lack of interferon-beta bioactivity is associated with the occurrence of relapses in multiple sclerosis. Eur. J. Neurol. 2009, 16, 1049-1052.
98. Kappos, L., Freedman, M.S., Polman, C.H., Edan, G., Hartung, H.-P., Miller, D.H., Montalbán, X., Barkhof, F., Radü, E.-W., Bauer, L., et al. Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: A 3-year follow-up analysis of the benefit study. Lancet 2007, 370, 389-397.
99. Kappos, L., Polman, C.H., Freedman, M.S., Edan, G., Hartung, H.P., Miller, D.H., Montalban, X., Barkhof, F., Bauer, L., Jakobs, P., et al. Treatment with interferon beta-1b delays conversion to clinically definite and mcdonald ms in patients with clinically isolated syndromes. Neurology 2006, 67, 1242-1249.
100. Huang, D.R. Challenges in randomized controlled trials and emerging multiple sclerosis therapeutics. Neurosci. Bull. 2015, 31, 745-754.
101. Fenu, G., Lorefice, L., Frau, F., Coghe, G.C., Marrosu, M.G., Cocco, E. Induction and escalation therapies in multiple sclerosis. Anti-Inflamm. Anti-Allergy Agents Med. Chem. 2015, 14, 26-34.
102. Kipp, M., Wagenknecht, N., Beyer, C., Samer, S., Wuerfel, J., Nikoubashman, O. Thalamus pathology in multiple sclerosis: From biology to clinical application. Cell. Mol. Life Sci. 2015, 72, 1127-1147.
103. Calabresi, P.A., Radue, E.W., Goodin, D., Jeffery, D., Rammohan, K.W., Reder, A.T., Vollmer, T., Agius, M.A., Kappos, L., Stites, T., et al. Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (freedoms ii): A double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Neurol. 2014, 13, 545-556.
104. Greenberg, B.M., Balcer, L., Calabresi, P.A., Cree, B., Cross, A., Frohman, T., Gold, R., Havrdova, E., Hemmer, B., Kieseier, B.C., et al. Interferon beta use and disability prevention in relapsing-remitting multiple sclerosis. JAMA Neurol. 2013, 70, 248-251.
105. Noyes, K., Weinstock-Guttman, B. Impact of diagnosis and early treatment on the course of multiple sclerosis. Am. J. Manag. Care 2013, 19, s321-s331.
106. Shirani, A., Zhao, Y., Karim, M.E., Evans, C., Kingwell, E., Van Der Kop, M.L., Oger, J., Gustafson, P., Petkau, J., Tremlett, H. Association between use of interferon beta and progression of disability in patients with relapsing-remitting multiple sclerosis. JAMA 2012, 308, 247-256.
107. Rommer, P.S., Stüve, O. Management of secondary progressive multiple sclerosis: Prophylactic treatment-past, present, and future aspects. Curr. Treat. Options Neurol. 2013, 15, 241-258.
108. Trojano, M., Pellegrini, F., Paolicelli, D., Fuiani, A., Zimatore, G.B., Tortorella, C., Simone, I.L., Patti, F., Ghezzi, A., Zipoli, V., et al. Real-life impact of early interferonβ therapy in relapsing multiple sclerosis. Ann. Neurol. 2009, 66, 513-520.
109. Goodin, D.S., Ebers, G.C., Cutter, G., Cook, S.D., O'Donnell, T., Reder, A.T., Kremenchutzky, M., Oger, J., Rametta, M., Beckmann, K., et al. Cause of death in ms: Long-term follow-up of a randomised cohort, 21 years after the start of the pivotal ifnβ-1b study. BMJ Open 2012, 2.
110. Goodin, D.S., Reder, A.T., Ebers, G.C., Cutter, G., Kremenchutzky, M., Oger, J., Langdon, D., Rametta, M., Beckmann, K., DeSimone, T.M., et al. Survival in ms a randomized cohort study 21 years after the start of the pivotal ifnβ-1b trial. Neurology 2012, 78, 1315-1322.
111. Mitsdoerffer, M., Kuchroo, V. New pieces in the puzzle: How does interferon-beta really work in multiple sclerosis? Ann. Neurol. 2009, 65, 487-488.
112. The IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993, 43, 655-661.
113. The IFNB Multiple Sclerosis Study Group, The University of British Columbia MS/MRI Analysis Group. Interferon beta-1b in the treatment of multiple sclerosis: Final outcome of the randomized controlled trial. Neurology 1995, 45, 1277-1285.
114. Yong, V.W., Giuliani, F., Xue, M., Bar-Or, A., Metz, L.M. Experimental models of neuroprotection relevant to multiple sclerosis. Neurology 2007, 68, S32-S37.
115. Wolinsky, J.S., Narayana, P.A., O’Connor, P., Coyle, P.K., Ford, C., Johnson, K., Miller, A., Pardo, L., Kadosh, S., Ladkani, D., et al. Glatiramer acetate in primary progressive multiple sclerosis: Results of a multinational, multicenter, double-blind, placebo-controlled trial. Ann. Neurol. 2007, 61, 14-24.
116. Wolinsky, J.S. Copolymer 1: A most reasonable alternative therapy for early relapsing-remitting multiple sclerosis with mild disability. Neurology 1995, 45, 1245-1247.
117. Neuhaus, O., Farina, C., Wekerle, H., Hohlfeld, R. Mechanisms of action of glatiramer acetate in multiple sclerosis. Neurology 2001, 56, 702-708.
118. Ragheb, S., Abramczyk, S., Lisak, D., Lisak, R. Long-term therapy with glatiramer acetate in multiple sclerosis: Effect on t-cells. Mult. Scler. 2001, 7, 43-47.
119. Haas, J., Korporal, M., Balint, B., Fritzsching, B., Schwarz, A., Wildemann, B. Glatiramer acetate improves regulatory t-cell function by expansion of naive CD4(+)CD25(+)Foxp3(+)CD31(+) t-cells in patients with multiple sclerosis. J. Neuroimmunol. 2009, 216, 113-117.
120. Johnson, K.P., Brooks, B.R., Cohen, J.A., Ford, C.C., Goldstein, J., Lisak, R.P., Myers, L.W., Panitch, H.S., Rose, J.W., Schiffer, R.B., et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: Results of a phase iii multicenter, double-blind placebo-controlled trial. Neurology 1995, 45, 1268-1276.
121. Gold, R., Kappos, L., Arnold, D.L., Bar-Or, A., Giovannoni, G., Selmaj, K., Tornatore, C., Sweetser, M.T., Yang, M., Sheikh, S.I., et al. Placebo-controlled phase 3 study of oral bg-12 for relapsing multiple sclerosis. N. Engl. J. Med. 2012, 367, 1098-1107.
122. Moharregh-Khiabani, D., Linker, R.A., Gold, R., Stangel, M. Fumaric acid and its esters: An emerging treatment for multiple sclerosis. Curr. Neuropharmacol. 2009, 7, 60-64.
123. Albrecht, P., Bouchachia, I., Goebels, N., Henke, N., Hofstetter, H.H., Issberner, A., Kovacs, Z., Lewerenz, J., Lisak, D., Maher, P., et al. Effects of dimethyl fumarate on neuroprotection and immunomodulation. J. Neuroinflamm. 2012, 9.
124. Palmer, A.M. Teriflunomide, an inhibitor of dihydroorotate dehydrogenase for the potential oral treatment of multiple sclerosis. Curr. Opin. Investig. Drugs 2010, 11, 1313-1323.
125. Korn, T., Magnus, T., Toyka, K., Jung, S. Modulation of effector cell functions in experimental autoimmune encephalomyelitis by leflunomide-mechanisms independent of pyrimidine depletion. J. Leukoc. Biol. 2004, 76, 950-960.
126. O’Connor, P., Wolinsky, J.S., Confavreux, C., Comi, G., Kappos, L., Olsson, T.P., Benzerdjeb, H., Truffinet, P., Wang, L., Miller, A., et al. Randomized trial of oral teriflunomide for relapsing multiple sclerosis. N. Engl. J. Med. 2011, 365, 1293-1303.
127. Sanvito, L., Constantinescu, C.S., Gran, B. Novel therapeutic approaches to autoimmune demyelinating disorders. Curr. Pharm. Des. 2011, 17, 3191-3201.
128. Yeh, E.A. Current therapeutic options in pediatric multiple sclerosis. Curr. Treat. Options Neurol. 2011, 13, 544-559.
129. O’Connor, P.W., Li, D., Freedman, M.S., Bar-Or, A., Rice, G.P.A., Confavreux, C., Paty, D.W., Stewart, J.A., Scheyer, R. A phase ii study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses. Neurology 2006, 66, 894-900.
130. Confavreux, C., O’Connor, P., Comi, G., Freedman, M.S., Miller, A.E., Olsson, T.P., Wolinsky, J.S., Bagulho, T., Delhay, J.-L., Dukovic, D., et al. Oral teriflunomide for patients with relapsing multiple sclerosis (tower): A randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurol. 2014, 13, 247-256.
131. Vermersch, P., Czlonkowska, A., Grimaldi, L.M., Confavreux, C., Comi, G., Kappos, L., Olsson, T.P., Benamor, M., Bauer, D., Truffinet, P., et al. Teriflunomide versus subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis: A randomised, controlled phase 3 trial. Mult. Scler. J. 2014, 20, 705-716.
132. Brinkmann, V., Davis, M.D., Heise, C.E., Albert, R., Cottens, S., Hof, R., Bruns, C., Prieschl, E., Baumruker, T., Hiestand, P., et al. The immune modulator fty720 targets sphingosine 1-phosphate receptors. J. Biol. Chem. 2002, 277, 21453-21457.
133. Mandala, S., Hajdu, R., Bergstrom, J., Quackenbush, E., Xie, J., Milligan, J., Thornton, R., Shei, G.J., Card, D., Keohane, C., et al. Alteration of lymphocyte trafficking by sphingosine-1-phosphate receptor agonists. Science 2002, 296, 346-349.
134. Matloubian, M., Lo, C.G., Cinamon, G., Lesneski, M.J., Xu, Y., Brinkmann, V., Allende, M.L., Proia, R.L., Cyster, J.G. Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on s1p receptor 1. Nature 2004, 427, 355-360.
135. Choi, J.W., Gardell, S.E., Herr, D.R., Rivera, R., Lee, C.W., Noguchi, K., Teo, S.T., Yung, Y.C., Lu, M., Kennedy, G., et al. Fty720 (fingolimod) efficacy in an animal model of multiple sclerosis requires astrocyte sphingosine 1-phosphate receptor 1 (s1p1) modulation. Proc. Natl. Acad. Sci. USA 2011, 108, 751-756.
136. Cohen, J.A., Barkhof, F., Comi, G., Hartung, H.P., Khatri, B.O., Montalban, X., Pelletier, J., Capra, R., Gallo, P., Izquierdo, G., et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N. Engl. J. Med. 2010, 362, 402-415.
137. Kappos, L., Radue, E.W., O’Connor, P., Polman, C., Hohlfeld, R., Calabresi, P., Selmaj, K., Agoropoulou, C., Leyk, M., Zhang-Auberson, L., et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N. Engl. J. Med. 2010, 362, 387-401.
138. Huang, B., Wang, Q.T., Song, S.S., Wu, Y.J., Ma, Y.K., Zhang, L.L., Chen, J.Y., Wu, H.X., Jiang, L., Wei, W. Combined use of etanercept and mtx restores CD4 + /CD8 + ratio and tregs in spleen and thymus in collagen-induced arthritis. Inflamm. Res. 2012, 61, 1229-1239.
139. Lenk, H., Muller, U., Tanneberger, S. Mitoxantrone: Mechanism of action, antitumor activity, pharmacokinetics, efficacy in the treatment of solid tumors and lymphomas, and toxicity. Anticancer Res. 1987, 7, 1257-1264.
140. Hartung, H.-P., Gonsette, R., Konig, N., Kwiecinski, H., Guseo, A., Morrissey, S.P., Krapf, H., Zwingers, T. Mitoxantrone in progressive multiple sclerosis: A placebo-controlled, double-blind, randomised, multicentre trial. Lancet 2002, 360, 2018-2025.
141. Edan, G., Miller, D., Clanet, M., Confavreux, C., Lyon-Caen, O., Lubetzki, C., Brochet, B., Berry, I., Rolland, Y., Froment, J.C., et al. Therapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: A randomised multicentre study of active disease using mri and clinical criteria. J. Neurol. Neurosurg. Psychiatry 1997, 62, 112-118.
142. Martinelli, V., Radaelli, M., Straffi, L., Rodegher, M., Comi, G. Mitoxantrone: Benefits and risks in multiple sclerosis patients. Neurol. Sci. 2009, 30, S167-S170.
143. Sheremata, W.A., Minagar, A., Alexander, J.S., Vollmer, T. The role of alpha-4 integrin in the aetiology of multiple sclerosis: Current knowledge and therapeutic implications. CNS Drugs 2005, 19, 909-922.
144. Rice, G.P.A., Hartung, H.P., Calabresi, P.A. Anti-α4 integrin therapy for multiple sclerosis: Mechanisms and rationale. Neurology 2005, 64, 1336-1342.
145. Klotz, L., Gold, R., Hemmer, B., Korn, T., Zipp, F., Hohlfeld, R., Kieseier, B.C., Wiendl, H. Diagnosis of multiple sclerosis 2010 revision of the mcdonald criteria. Nervenarzt 2011, 82, 1302-1309.
146. Jarius, S., Hohlfeld, R., Voltz, R. Diagnosis and therapy of multiple sclerosis—Update 2003. MMW Fortschr. Med. 2003, 145, 88-95.
147. Miller, D.H., Khan, O.A., Sheremata, W.A., Blumhardt, L.D., Rice, G.P.A., Libonati, M.A., Willmer-Hulme, A.J., Dalton, C.M., Miszkiel, K.A., O’Connor, P.W. A controlled trial of natalizumab for relapsing multiple sclerosis. N. Engl. J. Med. 2003, 348, 15-23.
148. Natalizumab: New drug. Multiple sclerosis: Risky market approval. Prescrire Int. 2008, 17, 7-10.
149. Frohman, E.M., Racke, M.K., Raine, C.S. Multiple sclerosis-the plaque and its pathogenesis. N. Engl. J. Med. 2006, 354, 942-955.
150. Hauser, S.L., Waubant, E., Arnold, D.L., Vollmer, T., Antel, J., Fox, R.J., Bar-Or, A., Panzara, M., Sarkar, N., Agarwal, S., et al. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N. Engl. J. Med. 2008, 358, 676-688.
151. Kappos, L., Li, D., Calabresi, P.A., O’Connor, P., Bar-Or, A., Barkhof, F., Yin, M., Leppert, D., Glanzman, R., Tinbergen, J., et al. Ocrelizumab in relapsing-remitting multiple sclerosis: A phase 2, randomised, placebo-controlled, multicentre trial. Lancet 2011, 378, 1779-1787.
152. Sorensen, P.S., Lisby, S., Grove, R., Derosier, F., Shackelford, S., Havrdova, E., Drulovic, J., Filippi, M. Safety and efficacy of ofatumumab in relapsing-remitting multiple sclerosis: A phase 2 study. Neurology 2014, 82, 573-581.
153. Bleeker, W.K., Munk, M.E., Mackus, W.J., van den Brakel, J.H., Pluyter, M., Glennie, M.J., van de Winkel, J.G., Parren, P.W. Estimation of dose requirements for sustained in vivo activity of a therapeutic human anti-cd20 antibody. Br. J. Haematol. 2008, 140, 303-312.
154. ClinicalTrials.gov. Identifier: NCT02792218 and NCT02792231. Available online: https://www.mdanderson. org/patients-family/diagnosis-treatment/clinical-trials.html (accessed on 20 June 2017).
155. U.S. Food & Drug Administration (FDA). Drugs@fda: FDA Approved Drug Products. Available online: http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=761053 (accessed on 20 June 2017).
156. Cohen, J.A., Coles, A.J., Arnold, D.L., Confavreux, C., Fox, E.J., Hartung, H.P., Havrdova, E., Selmaj, K.W., Weiner, H.L., Fisher, E., et al. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: A randomised controlled phase 3 trial. Lancet 2012, 380, 1819-1828.
157. Coles, A.J., Twyman, C.L., Arnold, D.L., Cohen, J.A., Confavreux, C., Fox, E.J., Hartung, H.P., Havrdova, E., Selmaj, K.W., Weiner, H.L., et al. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: A randomised controlled phase 3 trial. Lancet 2012, 380, 1829-1839.
158. Lycke, J. Monoclonal antibody therapies for the treatment of relapsing-remitting multiple sclerosis: Differentiating mechanisms and clinical outcomes. Ther. Adv. Neurol. Disord. 2015, 8, 274-293.
159. McAllister, L.D., Beatty, P.G., Rose, J. Allogeneic bone marrow transplant for chronic myelogenous leukemia in a patient with multiple sclerosis. Bone Marrow Transplant. 1997, 19, 395-397.
160. Mancardi, G., Saccardi, R. Autologous haematopoietic stem-cell transplantation in multiple sclerosis. Lancet Neurol. 2008, 7, 626-636.
161. Sormani, M.P., Muraro, P.A., Schiavetti, I., Signori, A., Laroni, A., Saccardi, R., Mancardi, G.L. Autologous hematopoietic stem cell transplantation in multiple sclerosis: A meta-analysis. Neurology 2017, 88, 2115-2122.
162. Yamout, B., Hourani, R., Salti, H., Barada, W., El-Hajj, T., Al-Kutoubi, A., Herlopian, A., Baz, E.K., Mahfouz, R., Khalil-Hamdan, R., et al. Bone marrow mesenchymal stem cell transplantation in patients with multiple sclerosis: A pilot study. J. Neuroimmunol. 2010, 227, 185-189.
163. Llufriu, S., Sepulveda, M., Blanco, Y., Marin, P., Moreno, B., Berenguer, J., Gabilondo, I., Martinez-Heras, E., Sola-Valls, N., Arnaiz, J.A., et al. Randomized placebo-controlled phase ii trial of autologous mesenchymal stem cells in multiple sclerosis. PLoS ONE 2014, 9, e113936.
164. Correale, J., Fiol, M. Bht-3009, a myelin basic protein-encoding plasmid for the treatment of multiple sclerosis. Curr. Opin. Mol. Ther. 2009, 11, 463-470.
165. Kang, Y., Sun, Y., Zhang, J., Gao, W., Kang, J., Wang, Y., Wang, B., Xia, G. Treg cell resistance to apoptosis in DNA vaccination for experimental autoimmune encephalomyelitis treatment. PLoS ONE 2012, 7, e49994.
166. Bar-Or, A., Vollmer, T., Antel, J., Arnold, D.L., Bodner, C.A., Campagnolo, D., Gianettoni, J., Jalili, F., Kachuck, N., Lapierre, Y., et al. Induction of antigen-specific tolerance in multiple sclerosis after immunization with DNA encoding myelin basic protein in a randomized, placebo-controlled phase 1/2 trial. Arch. Neurol. 2007, 64, 1407-1415.
167. Papadopoulou, A., Von Felten, S., Traud, S., Rahman, A., Quan, J., King, R., Garren, H., Steinman, L., Cutter, G., Kappos, L., et al. Evolution of ms lesions to black holes under DNA vaccine treatment. J. Neurol. 2012, 259, 1375-1382.
168. Xiang, S.D., Scholzen, A., Minigo, G., David, C., Apostolopoulos, V., Mottram, P.L., Plebanski, M. Pathogen recognition and development of particulate vaccines: Does size matter? Methods 2006, 40, 1-9.
169. Xiang, S.D., Selomulya, C., Ho, J., Apostolopoulos, V., Plebanski, M. Delivery of DNA vaccines: An overview on the use of biodegradable polymeric and magnetic nanoparticles. Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol. 2010, 2, 205-218.
170. Cappellano, G., Woldetsadik, A.D., Orilieri, E., Shivakumar, Y., Rizzi, M., Carniato, F., Gigliotti, C.L., Boggio, E., Clemente, N., Comi, C., et al. Subcutaneous inverse vaccination with plga particles loaded with a mog peptide and il-10 decreases the severity of experimental autoimmune encephalomyelitis. Vaccine 2014, 32, 5681-5689.
171. Al-Ghobashy, M.A., ElMeshad, A.N., Abdelsalam, R.M., Nooh, M.M., Al-Shorbagy, M., Laible, G. Development and pre-clinical evaluation of recombinant human myelin basic protein nano therapeutic vaccine in experimental autoimmune encephalomyelitis mice animal model. Sci. Rep. 2017, 7, 46468.
172. Crowe, P.D., Qin, Y., Conlon, P.J., Antel, J.P. Nbi-5788, an altered mbp83-99 peptide, induces a t-helper 2-like immune response in multiple sclerosis patients. Ann. Neurol. 2000, 48, 758-765.
173. Hartung, H.P., Kieseier, B.C., Hemmer, B. Purely systemically active anti-inflammatory treatments are adequate to control multiple sclerosis. J. Neurol. 2005, 252, v30-v37.
174. Kappos, L., Comi, G., Panitch, H., Oger, J., Antel, J., Conlon, P., Steinman, L., Comi, G., Kappos, L., Oger, J., et al. Induction of a non-encephalitogenic type 2 t helper-cell autoimmune response in multiple sclerosis after administration of an altered peptide ligand in a placebo-controlled, randomized phase ii trial. Nat. Med. 2000, 6, 1176-1182.
175. Bielekova, B., Goodwin, B., Richert, N., Cortese, I., Kondo, T., Afshar, G., Gran, B., Eaton, J., Antel, J., Frank, J.A., et al. Encephalitogenic potential of the myelin basic protein peptide (amino acids 83-99) in multiple sclerosis: Results of a phase ii clinical trial with an altered peptide ligand. Nat. Med. 2000, 6, 1167-1175.
176. Perera, C.J., Duffy, S.S., Lees, J.G., Kim, C.F., Cameron, B., Apostolopoulos, V., Moalem-Taylor, G. Active immunization with myelin-derived altered peptide ligand reduces mechanical pain hypersensitivity following peripheral nerve injury. J. Neuroinflamm. 2015, 12, 28.
177. Perera, C.J., Lees, J.G., Duffy, S.S., Makker, P.G., Fivelman, B., Apostolopoulos, V., Moalem-Taylor, G. Effects of active immunisation with myelin basic protein and myelin-derived altered peptide ligand on pain hypersensitivity and neuroinflammation. J. Neuroimmunol. 2015, 286, 59-70.
178. Tian, D.H., Perera, C.J., Apostolopoulos, V., Moalem-Taylor, G. Effects of vaccination with altered peptide ligand on chronic pain in experimental autoimmune encephalomyelitis, an animal model of multiple sclerosis. Front. Neurol. 2013, 4, 168.
179. Lourbopoulos, A., Deraos, G., Matsoukas, M., Touloumi, O., Giannakopoulou, A., Kalbacher, H., Grigoriadis, N., Apostolopoulos, V., Matsoukas, J. Cyclic mog 35-55 ameliorates clinical and neuropathological features of experimental autoimmune encephalomyelitis. Bioorg. Med. Chem. 2017.
180. Apostolopoulos, V., Pietersz, G.A., Loveland, B.E., Sandrin, M.S., McKenzie, I.F. Oxidative/reductive conjugation of mannan to antigen selects for t1 or t2 immune responses. Proc. Natl. Acad. Sci. USA 1995, 92, 10128-10132.
181. Apostolopoulos, V., Pietersz, G.A., McKenzie, I.F. Cell-mediated immune responses to muc1 fusion protein coupled to mannan. Vaccine 1996, 14, 930-938.
182. Apostolopoulos, V., Pietersz, G.A., Tsibanis, A., Tsikkinis, A., Drakaki, H., Loveland, B.E., Piddlesden, S.J., Plebanski, M., Pouniotis, D.S., Alexis, M.N., et al. Pilot phase iii immunotherapy study in early-stage breast cancer patients using oxidized mannan-muc1 [isrctn71711835]. Breast Cancer Res. 2006, 8, R27.
183. Apostolopoulos, V., Pietersz, G.A., Tsibanis, A., Tsikkinis, A., Stojanovska, L., McKenzie, I.F., Vassilaros, S. Dendritic cell immunotherapy: Clinical outcomes. Clin. Transl. Immunol. 2014, 3, e21.
184. Karanikas, V., Hwang, L.A., Pearson, J., Ong, C.S., Apostolopoulos, V., Vaughan, H., Xing, P.X., Jamieson, G., Pietersz, G., Tait, B., et al. Antibody and t cell responses of patients with adenocarcinoma immunized with mannan-muc1 fusion protein. J. Clin. Investig. 1997, 100, 2783-2792.
185. Vassilaros, S., Tsibanis, A., Tsikkinis, A., Pietersz, G.A., McKenzie, I.F., Apostolopoulos, V. Up to 15-year clinical follow-up of a pilot phase iii immunotherapy study in stage ii breast cancer patients using oxidized mannan-muc1. Immunotherapy 2013, 5, 1177-1182.
186. Loveland, B.E., Zhao, A., White, S., Gan, H., Hamilton, K., Xing, P.X., Pietersz, G.A., Apostolopoulos, V., Vaughan, H., Karanikas, V., et al. Mannan-muc1-pulsed dendritic cell immunotherapy: A phase i trial in patients with adenocarcinoma. Clin. Cancer Res. 2006, 12, 869-877.
187. Mitchell, P.L., Quinn, M.A., Grant, P.T., Allen, D.G., Jobling, T.W., White, S.C., Zhao, A., Karanikas, V., Vaughan, H., Pietersz, G., et al. A phase 2, single-arm study of an autologous dendritic cell treatment against mucin 1 in patients with advanced epithelial ovarian cancer. J. Immunother. Cancer 2014, 2, 16.
188. Day, S., Tselios, T., Androutsou, M.E., Tapeinou, A., Frilligou, I., Stojanovska, L., Matsoukas, J., Apostolopoulos, V. Mannosylated linear and cyclic single amino acid mutant peptides using a small 10 amino acid linker constitute promising candidates against multiple sclerosis. Front. Immunol. 2015, 6, 136.
189. Yannakakis, M.P., Simal, C., Tzoupis, H., Rodi, M., Dargahi, N., Prakash, M., Mouzaki, A., Platts, J.A., Apostolopoulos, V., Tselios, T.V. Design and synthesis of non-peptide mimetics mapping the immunodominant myelin basic protein (MBP83-96) epitope to function as t-cell receptor antagonists. Int. J. Mol. Sci. 2017, 18.